AI Healthcare Moves From Pilot to Practice as Real-World Deployments Accelerate Global Impact

Real-World Deployments Signal AI Healthcare Is Ready for Scale

The use of AI in healthcare has moved beyond novelty. Experts increasingly recognize AI algorithms, detection tools, and drug discovery methods as essential components in clinical practice. With medical errors still causing patient harm, AI is being used to reduce mistakes such as incorrect drug prescriptions or dosages.

Several tech and biotech companies are actively bringing AI healthcare innovations into real-world settings. Among them are Avant Technologies, Inc., Tempus AI, Inc., BioXcel Therapeutics, Inc., Healwell AI Inc., and WELL Health Technologies Corp.

AI's Transformative Potential in Healthcare

New research from Mass General Brigham demonstrated AI models predicting cancer survival outcomes by analyzing facial images. This example highlights AI’s potential to transform healthcare significantly. Market forecasts from Statista suggest the global AI healthcare market could grow from about $11 billion today to $188 billion by 2030, with a compound annual growth rate of 37%.

Avant Technologies' Vision AI Platform

Avant Technologies, in partnership with Ainnova Tech, is developing a predictive diagnostics platform called Vision AI. This platform aims to detect disease markers at the earliest stages, sometimes before symptoms appear, by combining AI with clinical data.

Most recently, Avant announced plans to incorporate a patented technology focused on early-stage dementia detection. This tool uses proprietary algorithms, custom hardware, and a quick five-minute blood test to identify dementia risk factors earlier than conventional clinical methods.

Avant is exploring licensing and acquisition options for this technology with global rights under consideration. Such a move would strengthen its position in neurodegenerative care and complement its broader efforts in chronic illness screening.

Vinicio Vargas, CEO of Ainnova and board member of Ai-nova Acquisition Corp., stated, "This accessible, fast, and scalable solution is designed to support early intervention and targeted treatment strategies, aiming to reach millions globally in the coming years."

Vision AI's Functionality and Goals

Vision AI is a non-invasive platform integrating retinal imaging, blood pressure data, and routine lab results to provide personalized health assessments. It estimates risks for chronic conditions like cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease.

By analyzing just two retinal images and vital signs, Vision AI runs four proprietary algorithms trained on over 2.3 million clinical records. The platform’s modular design keeps costs low and enables deployment in diverse clinical environments, including those with limited specialist access.

According to Vargas, "Our goal is early disease detection that is accessible and affordable, allowing preventive check-ups anywhere. We want to prevent the progression of risk factors before they develop into serious health issues."

Strategic Developments and Market Access

Avant is moving toward fully acquiring Ainnova Tech, its development partner. Both operate within Ai-nova Acquisition Corp., and merging would align leadership and simplify regulatory processes.

An important FDA pre-submission meeting is scheduled for July, aligning well with potential consolidation. This move supports Avant's strategy of rapid deployment in markets with fewer regulations and parallel progress toward FDA clearance for U.S. entry.

Vargas noted, "Entering the U.S. market will unlock major commercial potential. Early regulator engagement ensures that we proceed with speed, credibility, and a validated product."

Real-World Applications and Future Prospects

Vision AI is already in use in clinical settings across Latin America, including Chile, Mexico, and Brazil. These deployments provide valuable real-world data on safety, performance, and usability. The insights gained are driving continuous improvements.

Long term, Avant aims to consolidate various diagnostic tools into a single system capable of delivering early health insights from basic, non-invasive inputs. With detection sensitivity above 90% reported in NIH-cited research and global rights secured through Ai-nova Acquisition Corp., Vision AI is positioned as a scalable solution for both developed and underserved healthcare systems.

Dementia screening is entering the pipeline, with other modules under evaluation. Avant is transitioning from early validation to broader execution, preparing for international expansion and a future U.S. launch.

Tempus AI and Other Innovations

Tempus AI has supported nearly 1,500 research projects since 2015, including about 1,000 biopharma partnerships and 500 provider initiatives. Its biological modeling lab contributed to over 60 projects focused on therapy selection and drug discovery.

Founder and CEO Eric Lefkofsky emphasized Tempus’ mission to empower researchers with data and insights to improve outcomes, highlighting the company's scale of delivery.

Meanwhile, BioXcel Therapeutics' Phase 3 SERENITY At-Home trial for BXCL501, targeting agitation in bipolar disorder and schizophrenia, continues after positive safety board review. Over 200 patients self-administer treatment during episodes, with results expected in Q3 2025. The trial could support a supplemental New Drug Application for at-home use, addressing a significant unmet medical need.

Canadian Digital Health Innovations

Healwell AI and WELL Health Technologies have three subsidiaries—Pentavere, Intrahealth, and OceanMD—recognized as winners in Canada Health Infoway's 2025 Vendor Innovation Program. These projects focus on interoperability solutions that enhance clinical workflows and improve access to actionable patient data.

Dr. Alexander Dobranowski, CEO of Healwell, highlighted how these companies are advancing data-driven care coordination and streamlining workflows to improve patient outcomes. Their projects will deploy across multiple provinces, including rural and Indigenous communities.

Amir Javidan, CEO of WELLSTAR (a WELL Health subsidiary), praised OceanMD's recognition for digital innovation in healthcare delivery across Canada.

• Projects focus on real-world interoperability and clinical workflow improvement.
• Deployments cover diverse settings, supporting underserved populations.
• Recognition underscores leadership in advancing digital healthcare infrastructure.

This momentum in AI healthcare innovation points to growing adoption and practical impact in both diagnostics and care delivery worldwide.